Insider Trading June 15, 2026 05:10 PM

Dentsply Sirona Director McKeon Acquires $101,199 in Shares Amid Stock Near 52-Week Low

Insider purchase occurs as company reports mixed Q1 2026 results and expands distribution partnerships

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
XRAY

DENTSPLY SIRONA Inc. director Brian P. McKeon purchased 10,000 shares of common stock on June 12, 2026, at $10.12 per share, totaling $101,199. The acquisition adds to his existing holdings, bringing his indirect trust position to 10,000 shares and direct ownership to 28,887 shares. The transaction coincides with XRAY trading near its 52-week low of $9.40, down 33% over the past year, while the company maintains a 6.34% dividend yield and has paid dividends for 32 consecutive years.

Dentsply Sirona Director McKeon Acquires $101,199 in Shares Amid Stock Near 52-Week Low
XRAY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Brian P. McKeon acquired 10,000 shares of DENTSPLY SIRONA stock on June 12, 2026, at $10.12 per share, totaling $101,199. This purchase adds to his existing holdings, bringing his indirect trust position to 10,000 shares and direct ownership to 28,887 shares. The insider activity occurs while XRAY shares are trading near their 52-week low of $9.40, down 33% over the past year. Despite recent challenges, the company maintains a 6.34% dividend yield and has paid dividends for 32 consecutive years.
  • Dentsply Sirona reported mixed financial results for the first quarter of 2026, with revenue surpassing expectations at $880 million against a forecast of $842.58 million, but earnings per share falling short at $0.27 versus the projected $0.28. Needham maintained its Hold rating on Dentsply Sirona, citing execution risk despite the favorable revenue outcome. The firm noted that the company's earnings per share missed Street expectations by one cent.
  • Dentsply Sirona announced an expanded partnership with Nashville Dental, set to begin in August 2026. This agreement will include the distribution of Dentsply Sirona's connected technology solutions across a nine-state territory. These developments reflect the company's ongoing efforts to enhance its market presence and product distribution.

On June 12, 2026, DENTSPLY SIRONA Inc. (NASDAQ:XRAY) director Brian P. McKeon executed a purchase of 10,000 shares of the company's common stock. The transaction was valued at $101,199, with each share acquired at a price of $10.12. This acquisition increases McKeon's existing stake in the dental technology firm.

Following this purchase, McKeon's ownership structure includes an indirect holding of 10,000 shares through a trust, alongside a direct position of 28,887 shares of common stock. The insider activity occurs while XRAY shares are trading close to their 52-week low of $9.40, reflecting a 33% decline over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels. Despite recent challenges, the company pays a significant 6.34% dividend yield and has maintained dividend payments for 32 consecutive years.

In other recent news, Dentsply Sirona reported mixed financial results for the first quarter of 2026. The company's revenue surpassed expectations, reaching $880 million compared to the forecasted $842.58 million. However, earnings per share fell slightly short, coming in at $0.27 against a projected $0.28. Needham maintained its Hold rating on Dentsply Sirona, citing execution risk despite the favorable revenue outcome. The firm noted that the company's earnings per share missed Street expectations by one cent.

Additionally, Dentsply Sirona announced an expanded partnership with Nashville Dental, set to begin in August 2026. This agreement will include the distribution of Dentsply Sirona's connected technology solutions across a nine-state territory. These developments reflect the company's ongoing efforts to enhance its market presence and product distribution.

Risks

  • Dentsply Sirona reported mixed financial results for the first quarter of 2026, with revenue surpassing expectations at $880 million against a forecast of $842.58 million, but earnings per share falling short at $0.27 versus the projected $0.28. Needham maintained its Hold rating on Dentsply Sirona, citing execution risk despite the favorable revenue outcome. The firm noted that the company's earnings per share missed Street expectations by one cent.
  • XRAY shares are trading near their 52-week low of $9.40, down 33% over the past year. Despite recent challenges, the company maintains a 6.34% dividend yield and has paid dividends for 32 consecutive years. The stock appears undervalued at current levels according to InvestingPro analysis.

More from Insider Trading

Cadence Design Director James Plummer Executes $576K Share Sale Amid Strategic Expansion Jun 15, 2026 Lyell Immunopharma Executive Reduces Stake Amid Clinical Milestones Jun 15, 2026 Lyell Immunopharma CSO Executes Mandatory Stock Sale Amid Clinical Updates Jun 15, 2026 Accel Entertainment Executive Phelan Offloads $325K Stake Under Pre-Arranged Plan Jun 15, 2026 Lyell Immunophma CEO Lynn Seely Executes Automatic Stock Sale to Cover Tax Obligations Jun 15, 2026